Table 1.

Demographic and clinical characteristics of the Parkinson’s disease (PD) and spinocerebellar ataxia type 3 (SCA3) patients.

PD group (No.)	Age (years)	Sex	Disease duration (years)	Motor/total UPDRS (more affected side)	Hoehn and Yahr stage	Medication (daily dose in mg) (LED)
1	66	F	3	38/55 (L)	2.5	Levodopa 300 (300)
2	70	M	8	48/64 (L)	3	Levodopa 350, trihexyphenidyl 3, amantadine 300, rotigotine 4 (770)
3	67	F	7	18/22 (L)	2	Levodopa 300, biperiden 4, ropinirole PR 4 (380)
4	57	M	6	27/33 (L)	2	Levodopa 300, pramipexole 0.75, amantadine 300 (675)
5	79	F	5	32/45 (L)	2.5	Levodopa 100, amantadine 100, propranolol 20 (200)
6	82	M	5	27/41 (R)	2.5	Levodopa 300, entacapone 600, amantadine 100, propranolol 30 (499)
7	75	M	1	16/31 (R)	2	Levodopa 100 (100)
8	80	M	3	24/30 (L)	2	Levodopa 200 (200)
9	62	M	2	28/40 (R)	2	Levodopa 300, biperiden 3, ropinirole 0.75 (315)
10	53	M	3	15/26 (R)	2	Levodopa 200 (200)
SCA3 group (No.)	Age (years)	Sex	Disease duration (years)	Clinical rating scale for cerebellar functiona	Abnormal CAG repeat number	Medication (daily dose in mg) (LED)
1	47	M	20	13	73	Levodopa 100, amantadine 100, baclofen 20, piracetam 2,400 (200)
2	62	F	3	11	62	Amantadine 150, biperiden 3 (150)
3	43	M	16	21	82	Amantadine 300, trihexyphenidyl 4, tizanidine 9, flunarizine HCl 15 (300)
4	75	F	13	24	66	Alprazolam 0.25 (0)
5	30	F	4	12	76	Tizanidine 3, amantadine 300 (300)
6	59	F	10	22	71	None (0)
7	62	M	2	12	66	Piracetam 2,400 (0)
8	30	F	3	12	76	Amantadine 150 (150)
9	39	F	3	14	74	Levodopa 100, amantadine 100 (200)

^aThe rating scale was developed by S. Massaquoi and M. Hallett. A higher score represents a more severe cerebellar dysfunction. The maximal score of the scale is 30 [for a detail, see Wessel et al. (19)].

F, female; L, left; LED, l-DOPA equivalent dose (20); M, male; R, right; UPDRS, unified PD rating scale.